SEC Form 4 · accession 0001127602-18-020694
LEXICON PHARMACEUTICALS, INC. · LXRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James F Tessmer
Officer — VP, Finance & Accounting
Period of report
Jun 8, 2018
Accepted (ET)
Jun 12, 2018 · 4:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001062822
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 8, 2018 | M | 10,000 | $10.15 | A | 35,643 | D | |
| Common Stock | Jun 8, 2018 | S | 10,000 | $12.9076 | D | 25,643 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.15 | Jun 8, 2018 | M | 10,000 | D | — | Feb 12, 2019 | Common Stock | 10,000 | 11,428 | D |
Explanation of responses
- F1Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/12/2010) and vests 1/48th per month for each month of service thereafter.